JNJ — JOHNSON & JOHNSON
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 200406 ·
Last close
$278.70
Market Cap
$670.92B
52W High
$290.25
52W Low
$194.15
ADV30
7,687,925
Next earnings
2027-01-26
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 25,399,000,000 | 17,302,000,000 | 6,365,000,000 | 210,000,000 | 197,425,000,000 | 16,910,000,000 | 115,896,000,000 |
| Jun 2026 | 25,310,000,000 | 17,259,000,000 | 7,174,000,000 | 5,534,000,000 | 201,061,000,000 | 20,422,000,000 | 116,090,000,000 |
| Mar 2026 | 24,062,000,000 | 15,956,000,000 | 6,395,000,000 | 5,235,000,000 | 200,894,000,000 | 21,688,000,000 | 119,708,000,000 |
| Dec 2025 | 24,564,000,000 | 16,596,000,000 | 5,591,000,000 | 5,116,000,000 | 199,210,000,000 | 19,709,000,000 | 117,666,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$27,608,000,000
Investing CF
$-7,177,000,000
Financing CF
$-18,543,000,000
CapEx
$-5,380,000,000
Dividends Paid
$-12,621,000,000
Buybacks
$-8,075,000,000
EPS Diluted TTM
$8.63
As of
2026-10-25
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
$15,144,000,000
Receivables
$19,046,000,000
ST Investments
$336,000,000
EBIT TTM
$26,208,000,000
Pretax Income TTM
$25,196,000,000
Interest Exp TTM
$1,012,000,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$99,334,995,968
EBITDA
$34,502,000,640
Free Cash Flow
$18,501,875,712
Enterprise Value
$662,495,494,144
Total Cash
$17,227,999,232
Total Debt
$44,650,999,808
Shares Out
2,407,310,266
Trailing EPS
$6.59
Book Value
$33.87
ROE
20.0%
ROA
8.5%
Div Yield
2.03%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 94,193,000,000 | 25,596,000,000 | 26,804,000,000 | 199,210,000,000 | 117,666,000,000 | 81,544,000,000 | 24,530,000,000 |
| Dec 2024 | 88,821,000,000 | 21,249,000,000 | 14,066,000,000 | 180,104,000,000 | 108,614,000,000 | 71,490,000,000 | 24,266,000,000 |
| Dec 2023 | 85,159,000,000 | 22,009,000,000 | 35,153,000,000 | 167,558,000,000 | 98,784,000,000 | 68,774,000,000 | 22,791,000,000 |
| Dec 2022 | 79,990,000,000 | 21,013,000,000 | 17,941,000,000 | 187,378,000,000 | 110,574,000,000 | 76,804,000,000 | 21,194,000,000 |
TTM Snapshot
Revenues TTM
$97,929,000,000
NetIncome TTM
$21,037,000,000
OpCashFlow TTM
—
Assets (Latest)
$201,061,000,000
Forward EPS
$11.62
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $260.00 · spot: $272.70 · call volume: 8,280 · put volume: 5,890
Expected Move to 2027-01-15:
±$22.05
(8.09%) —
implied range
$250.65 –
$294.75
· ATM straddle on $270.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
| AZN | ASTRAZENECA PLC | $282.68B | $182.27 | — |
News headlines (Yahoo Finance, 1h cache)
Global Multiport Surgical Robot Market 2026 Report: Trends and Forecast to 2030 | Capitalize on 19.1% CAGR as Intuitive Surgical, Medtronic, J&J and CMR Surgical Advance AI Surgery
2026-11-18 14:57 · Yahoo
Global Abdominal Surgical Robot Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.9% CAGR as Intuitive Surgical, Medtronic, J&J, and CMR Surgical Advance AI
2026-11-18 14:56 · Yahoo
Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK
2026-11-18 14:35 · Yahoo
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-17 23:47 · Yahoo
2 of the Best Dividend Stocks to Buy With $5,000 in November
2026-11-17 23:46 · Yahoo
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
2026-11-17 18:50 · Yahoo
Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson
2026-11-17 17:14 · Yahoo
Johnson & Johnson's Planned Ollin Biosciences Acquisition to Serve as Growth Driver Past 2030, UBS Says
2026-11-17 16:35 · Yahoo
Guggenheim Names Top Biotech Stock Pick Following JNJ Latest Deal
2026-11-17 16:10 · Yahoo
J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts
2026-11-17 14:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.